SARS-COV-2 infekcija kod bolesnika sa Evansovim sindromom: nevidljivi neprijatelj ili saveznik?
Sažetak
Uvod. Tokom pandemije COVID-19 lečenje bolesnika sa autoimunskim bolestima veoma je izazovno, pre svega zbog nedostatka pouzdanih podataka. Prikaz bolesnika. Prikazana je dvadesetogodišnja COVID-19 pozitivna bolesnica koja se prethodno lečila od Evansovog sindroma. I pored činjenice da je bila lečena imunosupresivima (prednizon, azatioprin), zajedno sa romiplostimom, tokom celog toka infekcije kod bolesnice se nisu ispoljili simptomi. U krvnoj slici bolesnice uočena je trombocitoza tokom SARS-CoV-2 pozitivnosti, dok je broj trombocita pre infekcije bio ispod referentnog opsega. Bolesnica je praćena vrlo pažljivo, sa posebnim osvrtom na broj trombocita i eventualnu pojavu znakova tromboznih događaja. Zaključak. Neophodno je opreznije praćenje broja trombocita i doziranje romiplostima tokom SARS-CoV-2 infekcije kod bolesnika sa autoimunom trombocitopenijom.
Reference
Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, Laffan M, et al. Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol 2020; 189(6):1038‒43.
Bussel J, Cines D, Cooper N, Dunbar C, Michel M, Rodeghiero F. COVID-19 and ITP: Frequently Asked Questions. Washington (DC): American Society of Hematology; 2020.
Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, et al. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost 2020; 18(6):1469‒72.
Murt A, Eskazan AE, Yılmaz U, Ozkan T, Ar MC. COVID-19 presenting with immune thrombocytopenia: a case report and review of the literature. J Med Virol 2020; Doi: 10.1002/jmv.26138
Li M, Nguyen CB, Yeung Z, Sanchez K, Rosen D, Bushan S. Evans syndrome in a patient with COVID-19. Br J Haematol 2020; 190(2): e59‒e61.
World Health Organization. Clinical management of COVID-19. interim guidance. Geneva, Switzerland: World Health Organization; 2020. [cited 2020 Jun 12]. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19
Gao Y, Chen Y, Liu M, Shi S, Tian J. Impacts of immunosuppression and immunodeficiency on COVID-19: A systematic review and meta-analysis. J Infect 2020; 81(2): e93‒5.
Minotti C, Tirelli F, Barbieri E, Giaquinto C, Dona D. How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review. J Infect 2020; 81(1): e61‒6.
Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18(8): 1995‒2002.
Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost 2020; 18(5):1023‒6.
Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogetry AE, Waheed A, et al. COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection. Blood 2020; 136(4): 489‒500.
Machin N, Ragni MV, Comer DM, Yabes JG. Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study. Thromb Res 2018; 172: 80‒5.
Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, et al. Long‐term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: A pooled analysis of 13 clinical trials. Eur J Haematol 2013; 91(5): 423–36.
Audia S, Bach B, Samson M, Lakomy D, Bour JB, Burlet B, et al. Venous thromboembolic events during warm autoimmune hemolytic anemia. PLoS One 2018; 13(11): e0207218.